Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

FLGT

+ Watchlist+ Portfolio

Fulgent Genetics, Inc.

Regulated industrySells to businessesTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$24.21
52-Week Range
$13.46 – $31.04
Market Cap
$702.11M
P/E (TTM)
—
EPS (TTM)
-3.10
Dividend Yield
0.00%
Advanced Metrics
Price/Book
0.70
PEG Ratio
—
Return on Equity
-8.74%
Return on Assets
-6.68%
Gross Margin
33.82%
Operating Margin
-37.09%
Profit Margin
-27.53%
Current Ratio
5.34
Debt/Equity
0.01
Total Debt
$10.37M
Free Cash Flow
$9.73M
Revenue Growth
7.50%
Earnings Growth
—
Enterprise Value
$413.96M

Market Snapshot

About

Fulgent Genetics, Inc. is a technology company providing comprehensive genetic testing services for physicians, clinicians, and patients to diagnose rare genetic disorders and enable precision medicine. The company offers a broad menu of genetic tests including single-gene testing, multi-gene panels, exome sequencing, and genome sequencing across therapeutic areas such as oncology, reproductive health, cardiology, and neurology. Fulgent significantly expanded its operations during the COVID-19 pandemic by developing and deploying widespread diagnostic testing capabilities, though the company continues to focus on its core genetic testing business. The company operates CLIA-certified and CAP-accredited laboratories utilizing advanced sequencing technologies and bioinformatics platforms.